Skip to main content
OpenTrials

Clinical trial condition

Hepatitis C

Explore clinical trials studying Hepatitis C. Study availability and eligibility vary by location and protocol.

1,296 public trials 40 recruiting studies
Refine in advanced search Browse all conditions

Hepatitis C trial results

Completed

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

NCT01170962

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Alabama Liver & Digestive Specialists (Alds) Montgomery, Alabama, United States
  • Scripps Clinic La Jolla, California, United States
  • CLI Los Angeles, California, United States
  • Desta Digestive Disease Medical Center San Diego, California, United States
View all 72 locations
View Trial Details
Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

NCT01016912

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Local Institution Hiroshima, Japan
  • Local Institution Sapporo, Hokkaido, Japan
  • Local Institution Kawasaki-Shi, Kanagawa, Japan
  • Local Institution Suita-Shi, Osaka, Japan
View Trial Details
Completed

BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

NCT01389323

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • Alabama Liver & Digestive Specialists (Alds) Montgomery, Alabama, United States
  • Va Long Beach Healthcare System - 11 Long Beach, California, United States
  • Axis Clinical Trials Los Angeles, California, United States
  • Greater Los Angeles Healthcare System Los Angeles, California, United States
View all 36 locations
View Trial Details
Completed

Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

NCT01448044

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • Scti Research Foundation San Clemente, California, United States
  • Umass Memorial Medical Center Worcester, Massachusetts, United States
  • University Gastroenterology Providence, Rhode Island, United States
  • Metropolitan Research Annandale, Virginia, United States
View all 26 locations
View Trial Details
Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

NCT01616524

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • Precision Research Institute, Llc San Diego, California, United States
  • Medical Associates Research Group San Diego, California, United States
  • University Of California, San Francisco/Sf General Hospital San Francisco, California, United States
View all 124 locations
View Trial Details
Completed

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

NCT01973049

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • Scripps Clinic La Jolla, California, United States
  • Medical Associates Research Group San Diego, California, United States
  • Quest Clinical Research San Francisco, California, United States
  • University Of Colorado Denver & Hospital Aurora, Colorado, United States
View all 49 locations
View Trial Details
Completed

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

NCT01718158

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • Va Long Beach Healthcare System Long Beach, California, United States
  • Gastrointestinal Specialists Of Georgia Pc Marietta, Georgia, United States
  • Weill Cornell Medical College New York, United States
  • Premier Medical Group Of The Hudson Valley, Pc Poughkeepsie, New York, United States
View all 78 locations
View Trial Details
Completed

Ph IIA Study (SOC +/- NS5B)

NCT01193361

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Advanced Clinical Research Institute Anaheim, California, United States
  • Loyola University Medical Center Maywood, Illinois, United States
  • Mercy Medical Center Baltimore, Maryland, United States
  • Digestive Disease Associates, P.A. Baltimore, Maryland, United States
View Trial Details

Related conditions